文献速递泌尿生殖与妇科肿瘤放疗

局限期前列腺癌放疗后PSA升高的长期预后意义:聚焦总生存

Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
PubMed 文献 · Radiat Oncol · 2017-06-14

结果显示PSA bounce是生化控制和总生存的显著有利因素,而PSA复发后PSA倍增时间≤5个月与总生存显著较差相关。

要点

  • 放疗后2年内PSA升高多为良性PSA bounce,与更好的生化控制和总生存相关。
  • PSA bounce出现时间显著早于PSA复发(中位20个月 vs 32个月)。
  • PSA复发后PSA倍增时间≤5个月者总生存显著更差。

核心结论

  • 放疗后前2年内PSA升高通常可归类为良性PSA bounce,伴有利的无复发生存和总生存。
  • PSA倍增时间是复发诊断后总生存的重要预测因素。

研究设计与样本

  • 放疗结束后中位随访108个月。

主要发现

  • 有PSA bounce者10年生化控制率为83%,无bounce者为34%(p < 0.01)。
  • 有PSA bounce者10年总生存率为82%,无bounce者为59%(p < 0.01)。
  • PSA bounce出现的中位时间为放疗后20个月,PSA复发为32个月(p < 0.01)。
  • PSA复发者中,PSA倍增时间>5个月与≤5个月的10年总生存率分别为72%与36%(p < 0.01)。
  • PSA倍增时间中位数在有bounce者与PSA复发者分别为5.5个月与5.0个月(无统计学显著性)。

关键数值与推荐

  • PSA bounce定义为PSA升高至少0.2 ng/ml后自发回落至bounce前水平或更低。
  • 生化失败按Phoenix定义判定。
  • 多因素Cox回归分析显示bounce发生、高nadir和治疗方式(LDR-BT vs EBRT;HDR-BT+EBRT vs EBRT)为PSA复发的独立因素。

临床怎么用

  • 放疗后前2年内出现PSA升高且符合bounce定义者,可考虑良性bounce,避免过早判定生化失败。
  • PSA复发后应关注PSA倍增时间,≤5个月提示总生存较差,需加强随访和干预评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to evaluate the long-term prognostic significance of rising PSA levels, particularly focussing on overall survival. METHODS: Two hundred ninety-five patients with localized prostate cancer were either treated with low-dose-rate (LDR) brachytherapy with I-125 seeds as monotherapy (n = 94; 145Gy), high-dose-rate (HDR) brachytherapy with Ir-192 as a boost to external beam RT (n = 66; 50.4Gy in 1.8Gy fractions EBRT + 18Gy in 9Gy fractions HDR) or EBRT alone (70.2Gy in 1.8Gy fractions; n = 135). "PSA bounce" was defined as an increase of at least 0.2 ng/ml followed by spontaneous return to pre-bounce level or lower, biochemical failure was defined according to the Phoenix definition. RESULTS: Median follow-up after the end of radiotherapy was 108 months. A PSA bounce showed to be a significant factor for biochemical control (BC) and overall survival (OS) after ten years (BC10 of 83% with bounce vs. 34% without, p < 0.01; OS10 of 82% with bounce vs. 59% without bounce, p < 0.01). The occurrence of a bounce, a high nadir and the therapy modality (LDR-BT vs. EBRT and HDR-BT + EBRT vs. EBRT) proved to be independent factors for PSA recurrence in multivariate Cox regression analysis. A bounce was detected significantly earlier than a PSA recurrence (median 20 months vs. 32 months after RT; p < 0.01; median PSA doubling time 5.5 vs. 5.0 months, not significant). PSA doubling time was prognostically significant in case of PSA recurrence (OS10 of 72% vs. 36% with PSA doubling time ˃ 5 months vs. ≤ 5 months; p < 0.01). CONCLUSIONS: Rising PSA levels within the first two years can usually be classified as a benign PSA bounce, with favourable recurrence-free and overall survival rates. PSA doubling time is an important predictor for overall survival following the diagnosis of a recurrence.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Freiberger C, Berneking V, Vögeli TA, et al. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival. Radiat Oncol. 2017. PMID: 28615058. doi:10.1186/s13014-017-0837-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。